全文获取类型
收费全文 | 2240篇 |
免费 | 141篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 88篇 |
妇产科学 | 33篇 |
基础医学 | 268篇 |
口腔科学 | 51篇 |
临床医学 | 276篇 |
内科学 | 504篇 |
皮肤病学 | 18篇 |
神经病学 | 125篇 |
特种医学 | 260篇 |
外科学 | 212篇 |
综合类 | 27篇 |
预防医学 | 181篇 |
眼科学 | 22篇 |
药学 | 130篇 |
中国医学 | 7篇 |
肿瘤学 | 180篇 |
出版年
2023年 | 10篇 |
2022年 | 11篇 |
2021年 | 44篇 |
2020年 | 24篇 |
2019年 | 26篇 |
2018年 | 48篇 |
2017年 | 38篇 |
2016年 | 39篇 |
2015年 | 52篇 |
2014年 | 58篇 |
2013年 | 76篇 |
2012年 | 91篇 |
2011年 | 110篇 |
2010年 | 73篇 |
2009年 | 104篇 |
2008年 | 99篇 |
2007年 | 90篇 |
2006年 | 91篇 |
2005年 | 75篇 |
2004年 | 75篇 |
2003年 | 81篇 |
2002年 | 64篇 |
2001年 | 55篇 |
2000年 | 42篇 |
1999年 | 42篇 |
1998年 | 65篇 |
1997年 | 65篇 |
1996年 | 73篇 |
1995年 | 51篇 |
1994年 | 51篇 |
1993年 | 52篇 |
1992年 | 43篇 |
1991年 | 27篇 |
1990年 | 32篇 |
1989年 | 49篇 |
1988年 | 52篇 |
1987年 | 48篇 |
1986年 | 40篇 |
1985年 | 33篇 |
1984年 | 23篇 |
1983年 | 15篇 |
1982年 | 24篇 |
1981年 | 17篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 13篇 |
1976年 | 18篇 |
1975年 | 18篇 |
1974年 | 8篇 |
排序方式: 共有2389条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Francesco Landi Ettore Capoluongo Andrea Russo Graziano Onder Matteo Cesari Paola Lulli Angelo Minucci Marco Pahor Cecilia Zuppi Roberto Bernabei 《Growth hormone & IGF research》2007,17(1):58-66
CONTEXT: Increasing evidences from experimental and human studies suggest that the activity of the growth hormone (GH/insulin-like growth factor-I) axis may contribute to the age-related cognitive decline and poor cognition in late life. OBJECTIVE: The aim of the present study was to evaluate the relationship of total serum free IGF-I and its binding protein-3 with cognitive performance in older persons aged 80 years or older. DESIGN: Data are from baseline evaluation of the ilSIRENTE study (n=353). Cognitive performance was evaluated using five items enclosed in the Minimum Data Set for Home Care assessment form: short-term memory, procedural memory, cognitive skills in daily decision making, verbal expression, comprehension. Free insulin-like growth factor-I (free IGF-I) and IGF-binding protein-3 (IGFBP-3) in blood were measured. Analysis of covariance (ANCOVA) was used to examine the relationship between cognitive impairment and the serum free IGF-I and IGFBP-3 concentrations, after adjustment for potential confounding variables. RESULTS: After adjustment for potential confounders, which included age, gender, education, cerebrovascular disease, ischemic heart disease, congestive heart failure, hypertension, diabetes, depression, Parkinson diseases, thyroid diseases, smoking status, alcohol abuse, body mass index, and number of medications, individuals with verbal expression problems (n=20) and individuals with comprehension problems (n=24) had a significantly lower serum levels of readily dissociable IGF-I than participants without cognitive impairments. The serum IGFBP-3 presented the same behavior of free IGF-I. CONCLUSION: The present study suggests that among old-old subjects living in the community lower levels of total serum free IGF-I and IGFBP-3 are associated with impairment of cognitive performance. This finding suggests that the GH/IGF-I axis may play an important role in the age-related decline of cognitive performance. 相似文献
3.
K. Wilhelmsen D. Mirel K. Marder M. Bernstein A. Naini S. M. Leal L. J. Cote M.-X. Tang G. Freyer J. Graziano R. Mayeux 《Annals of neurology》1997,41(6):813-817
The cytochrome P450 mono-oxygenase gene, CYP2D6 on chromosome 22q13 (ch22q13), has been inconsistently associated with Parkinson's disease. Associations with CYP2D6 have either been absent altogether or have involved more than one polymorphism, many of which have the same metabolic effect on gene expression. We examined the association between CYP2D6 polymorphisms and Parkinson's disease in a case-control study and included 10 polymorphic dinucleotide repeat markers linked to CYP2D6 to determine whether the association was present or due to linkage disequilibrium. There was no association between any polymorphism of CYP2D6 and Parkinson's disease, but two of 10 dinucleotide repeat markers linked to CYP2D6 were associated with the disease. These results provide evidence to suggest that there may be an unidentified locus for susceptibility to Parkinson's disease that is in linkage disequilibrium with dinucleotide repeat markers mapping near CYP2D6 on ch22q13. 相似文献
4.
Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. 总被引:7,自引:0,他引:7
J H Graziano N J Lolacono T Moulton M E Mitchell V Slavkovich C Zarate 《The Journal of pediatrics》1992,120(1):133-139
We examined the efficacy and safety of meso-2,3-dimercaptosuccinic acid (DMSA) in children with markedly elevated blood lead (BPb) concentrations. Among 19 children with BPb concentrations of 50 to 69 micrograms/dl (2.41 to 3.33 mumol/L) who received a 5-day inpatient oral course of DMSA (1050 mg/m2 per day), the mean BPb concentration decreased by 61%; in four who received calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA) (1000 mg/m2 per day intravenously), it decreased by 45% (p less than 0.0007). Urinary lead excretion was comparable in both groups. Treatment with DMSA was more effective than treatment with CaNa2EDTA in restoring metabolic activity to the heme pathway and was well tolerated even among nine patients who received concomitant iron supplementation and two who had homozygous deficiency of glucose-6-phosphate dehydrogenase. On discharge, these 19 children received either no chelation therapy or DMSA, 350 or 700 mg/m2 per day for 14 days on an outpatient basis. After 14 days the mean BPb values for the no-chelation, low-DMSA, and high-DMSA groups were 73%, 66%, and 50% of the pretreatment values, respectively. We conclude that a 5-day oral course of DMSA is effective in the treatment of children with severe lead poisoning. In addition, on an outpatient basis the administration of DMSA, 700 mg/m2 per day, is capable of delaying the typical rebound in BPb values and should ultimately reduce the need for repeated hospitalizations. 相似文献
5.
6.
7.
8.
9.
10.